Ready to Use Cell Models
Two cryopreserved 96-well human co-culture assay kits to choose from - PrimeKit HUVECs + human dermal fibroblasts, and Stem Kit Endothelial Colony Forming Cells and Adipocyte Derived Stromal Cells.
Fully kinetic readout
Follow tube formation in real time for up to 2 weeks via fluorescent quantification of GFP-labelled endothelial cells
Automated image acquisition and processing
Acquire and analyze images using fully integrated Angiogenesis software module. Visualize kinetic plots in microplate views. Export metrics (tube length, tube area, branch points) to calculate EC50/IC50 values
Quantify tube formation and disruption
Study the inhibition of tube formation and/or investigate treatment effects on established networks. Quantify pro- and anti-angiogenic treatments
Concentration dependent vascular tube formation induced by Vasoactive Endothelial Growth Factor (VEGF) in PrimeKit HUVEC and human dermal fibroblast co-culture model. Upper left: Full time-course of VEGF induced vascular tube formation. Upper right: Microplate view to show 96-well assay layout and on plate consistency. VEGF was added at 60h. Abscissa: time (h), ordinate: tube length (mm/mm2). Lower left: Area under curve analysis of time-course data. Concentration-response curves (based on peak tube length) for VEGF and Avastin inhibition of VEGF (4 ng/ml) induced tube formation by Avastin (based on peak tube length). Lower right: Example image of VEGF (4 ng/ml) induced vascular structures.
Concentration-dependent disruption of established VEGF induced vascular tubes in StemKit Endothelial Colony Forming Cell & Adipocyte Derived Stromal Cell model. Upper left: Time-course for the effect of combretastatin (added at 96h) and suramin (100 micromolar, added at 96h) on established VEGF (20 ng/ml) induced tube formation. Upper right: Microplate view to show 96-well assay layout and on plate consistency (VEGF added at 0h and 96h, test agents added at 96h). Abscissa: time (h), ordinate: tube length (mm/mm2). IncuCyte fluorescent images for VEGF (20 ng/ml) alone (lower left) and in the the presence of the microtubule disrupting agent, Combretastatin (3 nM) (lower right).